Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C. Gelu-Simeon, M., Burlaud, A., Young, J., Pelletier, G., & Buffet, C. World J Gastroenterol, 15(3):328–33, January, 2009. abstract bibtex AIM: To study predictive factors of thyroid dysfunction associated with interferon-alpha (IFNalpha) therapy in chronic hepatitis C (CHC) and to describe its long-term evolution in a large population without previous thyroid dysfunction. METHODS: We performed a follow-up of thyroid function and detection of thyroid antibodies in 301 patients treated for CHC with IFNalpha from 1999 to 2004. RESULTS: Thyroid disorder developed in 30/301 (10%) patients with a mean delay of 6 +/- 3.75 mo: 13 patients had hyperthyroidism, 11 had hypothyroidism, and 6 had biphasic evolution. During a mean follow-up of 41.59 +/- 15.39 mo, 9 patients with hyperthyroidism, 3 with hypothyroidism, and 4 with biphasic evolution normalized thyroid function in 7.88 +/- 5.46 mo. Recovery rate of dysthyroidism was not modified by treatment discontinuation, but was better for patients with negative thyroid antibodies before antiviral treatment (P = 0.02). Women had significantly more dysthyroidism (P = 0.05). Positive thyroid peroxidase and thyroglobulin antibodies were more frequent before antiviral treatment in patients who developed dysthyroidism (P \textless 0.0003 and P = 0.0003, respectively). In a multivariate model, low fibrosis was found to be a predictive factor of dysthyroidism (P = 0.039). CONCLUSION: In this monocentric population of CHC, dysthyroidism, especially hyperthyroidism, developed in 10% of patients. Low fibrosis was found to be a predictive factor of dysthyroidism. Thyroid disorder recovered in 16/30 patients (53%) and recovery was better in the non-autoimmune form.
@article{gelu-simeon_evolution_2009,
title = {Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis {C}},
volume = {15},
issn = {1007-9327 (PRINT); 1007-9327 (LINKING)},
shorttitle = {Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis {C}},
abstract = {AIM: To study predictive factors of thyroid dysfunction associated with interferon-alpha (IFNalpha) therapy in chronic hepatitis C (CHC) and to describe its long-term evolution in a large population without previous thyroid dysfunction. METHODS: We performed a follow-up of thyroid function and detection of thyroid antibodies in 301 patients treated for CHC with IFNalpha from 1999 to 2004. RESULTS: Thyroid disorder developed in 30/301 (10\%) patients with a mean delay of 6 +/- 3.75 mo: 13 patients had hyperthyroidism, 11 had hypothyroidism, and 6 had biphasic evolution. During a mean follow-up of 41.59 +/- 15.39 mo, 9 patients with hyperthyroidism, 3 with hypothyroidism, and 4 with biphasic evolution normalized thyroid function in 7.88 +/- 5.46 mo. Recovery rate of dysthyroidism was not modified by treatment discontinuation, but was better for patients with negative thyroid antibodies before antiviral treatment (P = 0.02). Women had significantly more dysthyroidism (P = 0.05). Positive thyroid peroxidase and thyroglobulin antibodies were more frequent before antiviral treatment in patients who developed dysthyroidism (P {\textless} 0.0003 and P = 0.0003, respectively). In a multivariate model, low fibrosis was found to be a predictive factor of dysthyroidism (P = 0.039). CONCLUSION: In this monocentric population of CHC, dysthyroidism, especially hyperthyroidism, developed in 10\% of patients. Low fibrosis was found to be a predictive factor of dysthyroidism. Thyroid disorder recovered in 16/30 patients (53\%) and recovery was better in the non-autoimmune form.},
number = {3},
journal = {World J Gastroenterol},
author = {Gelu-Simeon, M. and Burlaud, A. and Young, J. and Pelletier, G. and Buffet, C.},
month = jan,
year = {2009},
keywords = {Adult, Aged, Agents/adverse, Antiviral, Autoantibodies/immunology, C/diagnosis/, Diseases/, Female, Fibrosis/pathology, Follow-Up, Hepatitis, Humans, Interferon-alpha/adverse, Male, Middle, Studies, Therapy, Thyroid, chemically, drug, effects/therapeutic, induced/classification/pathology, use},
pages = {328--33},
}
Downloads: 0
{"_id":"yHd5Ycj8W8oFGyqqE","bibbaseid":"gelusimeon-burlaud-young-pelletier-buffet-evolutionandpredictivefactorsofthyroiddisorderduetointerferonalphainthetreatmentofhepatitisc-2009","author_short":["Gelu-Simeon, M.","Burlaud, A.","Young, J.","Pelletier, G.","Buffet, C."],"bibdata":{"bibtype":"article","type":"article","title":"Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C","volume":"15","issn":"1007-9327 (PRINT); 1007-9327 (LINKING)","shorttitle":"Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C","abstract":"AIM: To study predictive factors of thyroid dysfunction associated with interferon-alpha (IFNalpha) therapy in chronic hepatitis C (CHC) and to describe its long-term evolution in a large population without previous thyroid dysfunction. METHODS: We performed a follow-up of thyroid function and detection of thyroid antibodies in 301 patients treated for CHC with IFNalpha from 1999 to 2004. RESULTS: Thyroid disorder developed in 30/301 (10%) patients with a mean delay of 6 +/- 3.75 mo: 13 patients had hyperthyroidism, 11 had hypothyroidism, and 6 had biphasic evolution. During a mean follow-up of 41.59 +/- 15.39 mo, 9 patients with hyperthyroidism, 3 with hypothyroidism, and 4 with biphasic evolution normalized thyroid function in 7.88 +/- 5.46 mo. Recovery rate of dysthyroidism was not modified by treatment discontinuation, but was better for patients with negative thyroid antibodies before antiviral treatment (P = 0.02). Women had significantly more dysthyroidism (P = 0.05). Positive thyroid peroxidase and thyroglobulin antibodies were more frequent before antiviral treatment in patients who developed dysthyroidism (P \\textless 0.0003 and P = 0.0003, respectively). In a multivariate model, low fibrosis was found to be a predictive factor of dysthyroidism (P = 0.039). CONCLUSION: In this monocentric population of CHC, dysthyroidism, especially hyperthyroidism, developed in 10% of patients. Low fibrosis was found to be a predictive factor of dysthyroidism. Thyroid disorder recovered in 16/30 patients (53%) and recovery was better in the non-autoimmune form.","number":"3","journal":"World J Gastroenterol","author":[{"propositions":[],"lastnames":["Gelu-Simeon"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Burlaud"],"firstnames":["A."],"suffixes":[]},{"propositions":[],"lastnames":["Young"],"firstnames":["J."],"suffixes":[]},{"propositions":[],"lastnames":["Pelletier"],"firstnames":["G."],"suffixes":[]},{"propositions":[],"lastnames":["Buffet"],"firstnames":["C."],"suffixes":[]}],"month":"January","year":"2009","keywords":"Adult, Aged, Agents/adverse, Antiviral, Autoantibodies/immunology, C/diagnosis/, Diseases/, Female, Fibrosis/pathology, Follow-Up, Hepatitis, Humans, Interferon-alpha/adverse, Male, Middle, Studies, Therapy, Thyroid, chemically, drug, effects/therapeutic, induced/classification/pathology, use","pages":"328–33","bibtex":"@article{gelu-simeon_evolution_2009,\n\ttitle = {Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis {C}},\n\tvolume = {15},\n\tissn = {1007-9327 (PRINT); 1007-9327 (LINKING)},\n\tshorttitle = {Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis {C}},\n\tabstract = {AIM: To study predictive factors of thyroid dysfunction associated with interferon-alpha (IFNalpha) therapy in chronic hepatitis C (CHC) and to describe its long-term evolution in a large population without previous thyroid dysfunction. METHODS: We performed a follow-up of thyroid function and detection of thyroid antibodies in 301 patients treated for CHC with IFNalpha from 1999 to 2004. RESULTS: Thyroid disorder developed in 30/301 (10\\%) patients with a mean delay of 6 +/- 3.75 mo: 13 patients had hyperthyroidism, 11 had hypothyroidism, and 6 had biphasic evolution. During a mean follow-up of 41.59 +/- 15.39 mo, 9 patients with hyperthyroidism, 3 with hypothyroidism, and 4 with biphasic evolution normalized thyroid function in 7.88 +/- 5.46 mo. Recovery rate of dysthyroidism was not modified by treatment discontinuation, but was better for patients with negative thyroid antibodies before antiviral treatment (P = 0.02). Women had significantly more dysthyroidism (P = 0.05). Positive thyroid peroxidase and thyroglobulin antibodies were more frequent before antiviral treatment in patients who developed dysthyroidism (P {\\textless} 0.0003 and P = 0.0003, respectively). In a multivariate model, low fibrosis was found to be a predictive factor of dysthyroidism (P = 0.039). CONCLUSION: In this monocentric population of CHC, dysthyroidism, especially hyperthyroidism, developed in 10\\% of patients. Low fibrosis was found to be a predictive factor of dysthyroidism. Thyroid disorder recovered in 16/30 patients (53\\%) and recovery was better in the non-autoimmune form.},\n\tnumber = {3},\n\tjournal = {World J Gastroenterol},\n\tauthor = {Gelu-Simeon, M. and Burlaud, A. and Young, J. and Pelletier, G. and Buffet, C.},\n\tmonth = jan,\n\tyear = {2009},\n\tkeywords = {Adult, Aged, Agents/adverse, Antiviral, Autoantibodies/immunology, C/diagnosis/, Diseases/, Female, Fibrosis/pathology, Follow-Up, Hepatitis, Humans, Interferon-alpha/adverse, Male, Middle, Studies, Therapy, Thyroid, chemically, drug, effects/therapeutic, induced/classification/pathology, use},\n\tpages = {328--33},\n}\n\n\n\n","author_short":["Gelu-Simeon, M.","Burlaud, A.","Young, J.","Pelletier, G.","Buffet, C."],"key":"gelu-simeon_evolution_2009","id":"gelu-simeon_evolution_2009","bibbaseid":"gelusimeon-burlaud-young-pelletier-buffet-evolutionandpredictivefactorsofthyroiddisorderduetointerferonalphainthetreatmentofhepatitisc-2009","role":"author","urls":{},"keyword":["Adult","Aged","Agents/adverse","Antiviral","Autoantibodies/immunology","C/diagnosis/","Diseases/","Female","Fibrosis/pathology","Follow-Up","Hepatitis","Humans","Interferon-alpha/adverse","Male","Middle","Studies","Therapy","Thyroid","chemically","drug","effects/therapeutic","induced/classification/pathology","use"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"http://bibbase.org/zotero/biblioial","dataSources":["ftoP3zPyb2N3b9Noc"],"keywords":["adult","aged","agents/adverse","antiviral","autoantibodies/immunology","c/diagnosis/","diseases/","female","fibrosis/pathology","follow-up","hepatitis","humans","interferon-alpha/adverse","male","middle","studies","therapy","thyroid","chemically","drug","effects/therapeutic","induced/classification/pathology","use"],"search_terms":["evolution","predictive","factors","thyroid","disorder","due","interferon","alpha","treatment","hepatitis","gelu-simeon","burlaud","young","pelletier","buffet"],"title":"Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C","year":2009}